Vir Biotechnology, Inc. (NASDAQ:VIR) Position Increased by Barclays PLC

Barclays PLC increased its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 1.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 550,186 shares of the company’s stock after buying an additional 7,287 shares during the quarter. Barclays PLC owned about 0.40% of Vir Biotechnology worth $4,121,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its stake in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the period. Innealta Capital LLC acquired a new stake in Vir Biotechnology in the 2nd quarter valued at approximately $32,000. nVerses Capital LLC bought a new stake in Vir Biotechnology during the 3rd quarter valued at $56,000. Magnetar Financial LLC acquired a new position in Vir Biotechnology during the 2nd quarter worth $95,000. Finally, Quest Partners LLC grew its stake in shares of Vir Biotechnology by 142.1% in the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after purchasing an additional 7,452 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on VIR shares. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Barclays reduced their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.40.

Vir Biotechnology Stock Down 0.4 %

Shares of VIR stock opened at $7.34 on Monday. The stock has a 50-day simple moving average of $8.02 and a 200 day simple moving average of $8.53. The stock has a market capitalization of $1.01 billion, a P/E ratio of -1.87 and a beta of 0.49. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. During the same quarter last year, the business posted ($1.22) EPS. The business’s revenue for the quarter was down 9.8% on a year-over-year basis. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).